Cargando…
Vulvar carcinoma: dilemma, debates, and decisions
Vulvar carcinoma is a rare and aggressive gynecological malignancy. It affects elderly females, with the mean age at diagnosis being 55–60 years. Regional metastasis to inguinal lymph nodes is common. There is a high incidence of pelvic node involvement, especially in those with pathologically posit...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765975/ https://www.ncbi.nlm.nih.gov/pubmed/29386916 http://dx.doi.org/10.2147/CMAR.S143316 |
_version_ | 1783292302953807872 |
---|---|
author | Mitra, Swarupa Sharma, Manoj Kumar Kaur, Inderjeet Khurana, Ruparna Modi, Kanika Batra Narang, Raman Mandal, Avik Dutta, Soumya |
author_facet | Mitra, Swarupa Sharma, Manoj Kumar Kaur, Inderjeet Khurana, Ruparna Modi, Kanika Batra Narang, Raman Mandal, Avik Dutta, Soumya |
author_sort | Mitra, Swarupa |
collection | PubMed |
description | Vulvar carcinoma is a rare and aggressive gynecological malignancy. It affects elderly females, with the mean age at diagnosis being 55–60 years. Regional metastasis to inguinal lymph nodes is common. There is a high incidence of pelvic node involvement, especially in those with pathologically positive inguinal nodes. Surgery appears to be the only curative treatment option in the early stages of the disease. But in most patients, surgery is associated with considerable morbidities and psychosexual issues. Hence, in the quest for a less morbid form of treatment, multimodality approaches with various combinations of surgery, chemotherapy, and radiation therapy have been suggested for advanced vulvar cancers. Due to the low incidence of the disease, the level of evidence for the success of these treatment modalities is poor. In countries like India, a heterogeneous incidence of vulvar carcinoma exists across the country, with patients presenting at advanced stages when the option of surgery is often supplemented or replaced by chemotherapy and radiotherapy. In this review, we attempt to study the available published literature and trials and discuss the treatment options in various stages of vulvar carcinoma. |
format | Online Article Text |
id | pubmed-5765975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57659752018-01-31 Vulvar carcinoma: dilemma, debates, and decisions Mitra, Swarupa Sharma, Manoj Kumar Kaur, Inderjeet Khurana, Ruparna Modi, Kanika Batra Narang, Raman Mandal, Avik Dutta, Soumya Cancer Manag Res Review Vulvar carcinoma is a rare and aggressive gynecological malignancy. It affects elderly females, with the mean age at diagnosis being 55–60 years. Regional metastasis to inguinal lymph nodes is common. There is a high incidence of pelvic node involvement, especially in those with pathologically positive inguinal nodes. Surgery appears to be the only curative treatment option in the early stages of the disease. But in most patients, surgery is associated with considerable morbidities and psychosexual issues. Hence, in the quest for a less morbid form of treatment, multimodality approaches with various combinations of surgery, chemotherapy, and radiation therapy have been suggested for advanced vulvar cancers. Due to the low incidence of the disease, the level of evidence for the success of these treatment modalities is poor. In countries like India, a heterogeneous incidence of vulvar carcinoma exists across the country, with patients presenting at advanced stages when the option of surgery is often supplemented or replaced by chemotherapy and radiotherapy. In this review, we attempt to study the available published literature and trials and discuss the treatment options in various stages of vulvar carcinoma. Dove Medical Press 2018-01-09 /pmc/articles/PMC5765975/ /pubmed/29386916 http://dx.doi.org/10.2147/CMAR.S143316 Text en © 2018 Mitra et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Mitra, Swarupa Sharma, Manoj Kumar Kaur, Inderjeet Khurana, Ruparna Modi, Kanika Batra Narang, Raman Mandal, Avik Dutta, Soumya Vulvar carcinoma: dilemma, debates, and decisions |
title | Vulvar carcinoma: dilemma, debates, and decisions |
title_full | Vulvar carcinoma: dilemma, debates, and decisions |
title_fullStr | Vulvar carcinoma: dilemma, debates, and decisions |
title_full_unstemmed | Vulvar carcinoma: dilemma, debates, and decisions |
title_short | Vulvar carcinoma: dilemma, debates, and decisions |
title_sort | vulvar carcinoma: dilemma, debates, and decisions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765975/ https://www.ncbi.nlm.nih.gov/pubmed/29386916 http://dx.doi.org/10.2147/CMAR.S143316 |
work_keys_str_mv | AT mitraswarupa vulvarcarcinomadilemmadebatesanddecisions AT sharmamanojkumar vulvarcarcinomadilemmadebatesanddecisions AT kaurinderjeet vulvarcarcinomadilemmadebatesanddecisions AT khuranaruparna vulvarcarcinomadilemmadebatesanddecisions AT modikanikabatra vulvarcarcinomadilemmadebatesanddecisions AT narangraman vulvarcarcinomadilemmadebatesanddecisions AT mandalavik vulvarcarcinomadilemmadebatesanddecisions AT duttasoumya vulvarcarcinomadilemmadebatesanddecisions |